FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297848028> ?p ?o ?g. }

• W4297848028 abstract "Abstract Purpose To determine whether six cycles of FEC3-D3 has a comparable efficacy to eight of AC4-D4. Methods The enrolled patients (pts) were clinically diagnosed with stage II or III breast cancer. The primary endpoint was a pathologic complete response (pCR), and the secondary endpoints were 3-year disease-free survival (3Y DFS), toxicities, and health-related quality of life (HRQoL). Results Among the 248 pts enrolled, one case was ineligible for screening; 10 discontinued treatment due to progressive disease (7 and 3 in the AC4-D4 and FEC3-D3 arms), 16 dropped out due to a withdrawal of consent, and 3 were unable to complete the study (2 and 1 in the AC4-D4 and FEC3-D3 arms). The 218 pts who completed the surgery were included in the current analysis. The baseline characteristics of these subjects were well balanced between the two arms. By ITT analysis, pCR was achieved in 15/121 (12.4%) pts in the FEC3-D3 arm and 18/126 (14.3%) in the AC4-D4 arm ( P = 0.40). With a median follow up of 64.1 months, the 3-year DFS was comparable between the two arms (77.0% in FEC3-D3 vs. 74.9% in AC4-D4; P = 0.82). The most common adverse event (AE) was Grade 3/4 neutropenia, which arose in 27/126 (21.4%) AC4-D4 arm pts vs 23/121 (19.0%) FEC3-D3 arm cases. The primary HRQoL domains were similar between the two groups (FACT-B scores at baseline, P = 0.35; at the midpoint of NACT, P = 0.20; at the completion of NACT, P = 0.44). Conclusion Both NACT AC4-D4 and FEC3-D3 show comparable outcomes in terms of pCR, three-year DFS, toxicities, and QoL Shorter neo-adjuvant FEC3-D3 could be an alternative to AC4-D4 for stage II or III operable breast cancer. Trial registration ClinicalTrials.gov NCT02001506. Registered December 5,2013 https://clinicaltrials.gov/ct2/show/NCT02001506" @default.
• W4297848028 created "2022-10-01" @default.
• W4297848028 creator A5007364197 @default.
• W4297848028 creator A5007992707 @default.
• W4297848028 creator A5010518834 @default.
• W4297848028 creator A5026459010 @default.
• W4297848028 creator A5030834546 @default.
• W4297848028 creator A5032349144 @default.
• W4297848028 creator A5038037948 @default.
• W4297848028 creator A5049348377 @default.
• W4297848028 creator A5072174881 @default.
• W4297848028 creator A5076623237 @default.
• W4297848028 creator A5083020137 @default.
• W4297848028 date "2022-09-08" @default.
• W4297848028 modified "2023-10-15" @default.
• W4297848028 title "Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-Shorter; NCT02001506)" @default.
• W4297848028 cites W1712386042 @default.
• W4297848028 cites W1760303814 @default.
• W4297848028 cites W1857624176 @default.
• W4297848028 cites W1917204850 @default.
• W4297848028 cites W193386846 @default.
• W4297848028 cites W1955397179 @default.
• W4297848028 cites W1985048372 @default.
• W4297848028 cites W2050395435 @default.
• W4297848028 cites W2068724174 @default.
• W4297848028 cites W2075894019 @default.
• W4297848028 cites W2077028455 @default.
• W4297848028 cites W2087179076 @default.
• W4297848028 cites W2095861620 @default.
• W4297848028 cites W2113242459 @default.
• W4297848028 cites W2115228053 @default.
• W4297848028 cites W2120861328 @default.
• W4297848028 cites W2127232551 @default.
• W4297848028 cites W2130373334 @default.
• W4297848028 cites W2139510434 @default.
• W4297848028 cites W2140654333 @default.
• W4297848028 cites W2147415463 @default.
• W4297848028 cites W2157706516 @default.
• W4297848028 cites W2162760540 @default.
• W4297848028 cites W2735812822 @default.
• W4297848028 cites W2946054739 @default.
• W4297848028 cites W2966373819 @default.
• W4297848028 cites W3044857394 @default.
• W4297848028 cites W3130416374 @default.
• W4297848028 doi "https://doi.org/10.21203/rs.3.rs-1998190/v1" @default.
• W4297848028 hasPublicationYear "2022" @default.
• W4297848028 type Work @default.
• W4297848028 citedByCount "0" @default.
• W4297848028 crossrefType "posted-content" @default.
• W4297848028 hasAuthorship W4297848028A5007364197 @default.
• W4297848028 hasAuthorship W4297848028A5007992707 @default.
• W4297848028 hasAuthorship W4297848028A5010518834 @default.
• W4297848028 hasAuthorship W4297848028A5026459010 @default.
• W4297848028 hasAuthorship W4297848028A5030834546 @default.
• W4297848028 hasAuthorship W4297848028A5032349144 @default.
• W4297848028 hasAuthorship W4297848028A5038037948 @default.
• W4297848028 hasAuthorship W4297848028A5049348377 @default.
• W4297848028 hasAuthorship W4297848028A5072174881 @default.
• W4297848028 hasAuthorship W4297848028A5076623237 @default.
• W4297848028 hasAuthorship W4297848028A5083020137 @default.
• W4297848028 hasBestOaLocation W42978480281 @default.
• W4297848028 hasConcept C121608353 @default.
• W4297848028 hasConcept C126322002 @default.
• W4297848028 hasConcept C141071460 @default.
• W4297848028 hasConcept C168563851 @default.
• W4297848028 hasConcept C197934379 @default.
• W4297848028 hasConcept C203092338 @default.
• W4297848028 hasConcept C2776694085 @default.
• W4297848028 hasConcept C2776755627 @default.
• W4297848028 hasConcept C2777063308 @default.
• W4297848028 hasConcept C2778822529 @default.
• W4297848028 hasConcept C2778850193 @default.
• W4297848028 hasConcept C2781190966 @default.
• W4297848028 hasConcept C2781413609 @default.
• W4297848028 hasConcept C71924100 @default.
• W4297848028 hasConceptScore W4297848028C121608353 @default.
• W4297848028 hasConceptScore W4297848028C126322002 @default.
• W4297848028 hasConceptScore W4297848028C141071460 @default.
• W4297848028 hasConceptScore W4297848028C168563851 @default.
• W4297848028 hasConceptScore W4297848028C197934379 @default.
• W4297848028 hasConceptScore W4297848028C203092338 @default.
• W4297848028 hasConceptScore W4297848028C2776694085 @default.
• W4297848028 hasConceptScore W4297848028C2776755627 @default.
• W4297848028 hasConceptScore W4297848028C2777063308 @default.
• W4297848028 hasConceptScore W4297848028C2778822529 @default.
• W4297848028 hasConceptScore W4297848028C2778850193 @default.
• W4297848028 hasConceptScore W4297848028C2781190966 @default.
• W4297848028 hasConceptScore W4297848028C2781413609 @default.
• W4297848028 hasConceptScore W4297848028C71924100 @default.
• W4297848028 hasLocation W42978480281 @default.
• W4297848028 hasOpenAccess W4297848028 @default.
• W4297848028 hasPrimaryLocation W42978480281 @default.
• W4297848028 hasRelatedWork W1858470829 @default.
• W4297848028 hasRelatedWork W1990777236 @default.
• W4297848028 hasRelatedWork W2008190193 @default.
• W4297848028 hasRelatedWork W2062530500 @default.
• W4297848028 hasRelatedWork W2133332025 @default.
• W4297848028 hasRelatedWork W2138054646 @default.
• W4297848028 hasRelatedWork W2141429974 @default.
• W4297848028 hasRelatedWork W2560682459 @default.

• next